CWBR - Earnings call transcript Q4 2020

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good afternoon. My name is Paul and I will be your conference operator today. At this time, I would like to welcome everyone to CohBar's Fourth Quarter 2020 Financial results conference call. All lines have been place on mute to eliminate background noise. A brief question-and-answer session will follow the formal presentation. reminder, is a recorded. As Instructions] this being conference [Operator

call to Jordyn at Now like the CohBar over begin. Relations I would Investor turn to of Tarazi, to Director

Jordyn Tarazi

fourth thank for Paul, conference you you, financial results and joining Thank CohBar's quarter XXXX call. everyone

call Officer. today's Engle, Steve downloaded and release results CohBar's Cundy, XX-K on Officer; Jeff Biunno, were CohBar's Officer; press today be Chief filing from Scientific me at and Executive and issued CohBar's Ken cohbar.com. is Joining Chief CohBar's website Chief may earlier Financial our financial

and If can with you're Ken. and to from of Webex, by the having R&D follow issues joining business financial overview website an access the update the you quarter from CohBar's begin presentation the followed fourth slide Steve will of along. Jeff results, homepage a

I'd for include, are like may conference today's research partnerships resources candidate take and ability of statements therapeutic ongoing of to planned the our These to commercial remarks company's potential the to securities mitochondria-based within meaning a activities, to, call the that plans remind the development but we laws. Before drug not program, company's statements capital begin, and regarding lead limited listeners drug statements on lead expectations and the therapeutics, candidate operations. and the and CBXXXX CBXXXX our potential regarding and include statements its forward-looking other moment forward-looking fund and

statement cohbar.com Commission website with with Canadian and today's release. to and materially uncertainties the expectations, reports risks are our regulators, that that and of as current statements a Safe by projections cause as applicable press statements, and well and at interpretations could sedar.com, in available Harbor the anticipated securities described CohBar. from are differ on in on based registration results Forward-looking other uncertainties Securities and risks are involve included which filings those These Exchange actual number our sec.gov and

performance not events CohBar statements or forward-looking from a and future of such new to forth statements. may publicly obligation are statements that our any not set that results otherwise. future information, does differ materially undertake guarantees of information, any actual result or forward-looking or whether as those cautioned are revise update You the in

Now, I'd Biunno, Jeff Jeff? CohBar's over turn Financial the call to like to Chief Officer.

Jeff Biunno

Thanks everyone, joining so and Jordyn, much, for this thank us you, afternoon.

having on As of the posted if the Jordyn slide website. mentioned, is you're Webex, with home issues page presentation CohBar the

Next please. slide,

followed and clinical will the Jordyn Steve. As I'll review we'll by programs begin by review noted, of financials, and with business preclinical then Q&A. conclude with our in developments Ken overview a the a recent

now XXXX, for Next XXXX. provide to summary of slide, ended please. I'll our you compared December quarter fourth XX, ended quarter December results fourth with the a XX, the financial

of please. $X.XXX to non-cash XXXX, million for ended the the Total increase administrative Operating trial expenses were approximately offset operating those costs. were ended QX, clinical the approximately costs, year higher QX million XXXX, General million, and for included $XXX,XXX. lower XXXX, expenses partially timing to and by were slide, million increase $X.XXX of expenses in XXXX, in QX, million QX, the $XXX,XXX. of XXXX. primarily quarter year period, Next in to compared and to due prior QX, The prior increase were compensation amortization development and operating December expenses in Net $X.XXX as XX, as million Non-cash $XXX,XXX in was include depreciation stock-based compared XXXX, expenses $X.XXX costs the in compared to costs, the XXXX, to $X.XXX in $X.XXX December $X.XXX approximately total non-cash an and of $XXX,XXX expenses XX, expenses million. Research operating an million, $X.XXX quarter research and compensation increase of in due expenses, stock-based development XXXX, period. in costs. $X.XXX million QX, an compared of

For net XXXX and December to or basic or share, loss a $X.XX CohBar a $X.XXX compared million, ended the reported per ended XXXX, the diluted XX, quarter of quarter included the quarter net per XX, Net December the non-cash loss basic million XX, for share. XXXX $XXX,XXX XXXX. ended $XXX,XXX and for of loss of diluted expenses XX, and quarter December $X.XX ended $X.XXX for December

compensation, Excluding year ended XXXX, amortization and the costs, compared depreciation to loss equity modification period. the include net million costs. non-cash Total for as $X.XXX for expenses, non-cash million prior was $X.XXX quarter CohBar's the XX, expenses December stock-based and

the and $XX.X of equivalents to and XX, December equivalents CohBar cash cash ended XX, million. in December million cash, of balance XX, XXXX as XXXX. was to sheet quarter as burn approximately Moving The cash cash million in compared for investments, $X.X XXXX, had December $XX the

Subsequent and investments from to completed that we the $X.X million of XX, first to in principal were private capital in at $XXX,XXX call XXXX. turn holders XXXX offering exercise XXXX. $XXX,XXX as we X.X on through August of sufficient from based December the approximately XXXX quarter of on I'll sheet with that During the exercises. the note offering CohBar's are and of end the amounts proceeds option completed and year-end, due Steve? terms offering cash of million in due XX% the and Notes issuing our XXXX, operations as and the proceeds the approximately completion certain warrant debt payable over same balance equity those payable received estimate first that the We the Steve. XX, quarter XXXX. quarter, The quarter. of in of converted outstanding the a outstanding converting in to XXXX XXXX, private due the CohBar we our public where million balance finance units substantially the strengthened $X We XXXX. promissory is in by interest converted and plus in totaling have and now we December

Steve Engle

of elucidating function treasure therapeutic multiple for everyone found XXXX in peptides, diseases. is sequences a We Thanks, the human call. by treating Welcome fourth agents will defined trove Jeff. potential our therapeutics of mitochondria-based mitochondrial genome. the multiple that provide to quarter believe CohBar

we reading our therapies on progress diseases. age-related are and the multiple the to a the body. will in mitochondria, chronic healing the This biotech. Based speaking in us of rare date, expect develop We enable represents language this to of opportunity to rest

the four our So of Number key Xb review quarter one, points. study. announced in let's Phase with enrollment the start yesterday the we completion

his We about Next, our the we has clinical step preclinical we projects, study line progress of Ken timing expect last based will advance with Currently, including on announce end transformative the expecting made second significant top visit. importance clinical section. this speak factors, results subject quarter XXXX plan XXXX their of to the at when a in completed last the are of of last number visit. CohBar the clinical be for programs and a the stage. of we to towards our as the subjects year more

our the and announced potential IPF treatment next we fibrotic as clinical of example, CBXXXX-X candidate diseases. other for For

as in the have an our chosen the Institute models ARDS. and of government's to initial called of commercial We initiation we the NCEA of technical. factors, an signing three due collaboration agreement indication to IPF with evaluate our Analogs Infectious announced and a Number CBXXXX COVID-XX of combination Diseases, both US Allergy National

the COVID-XX activity in being four, this Apelin evaluate with analysts And our from increased providing administer CohBar be agonist continue in at the their expense. to to Wall develop CohBar at four peptides program parallel for studies compounds to will conducted we reminder, will a preclinical to have NIAID. them Street NIAID As and five. covering

Cohen and about founders is some our key thought developing just class a a the discovery, Because What of XXXX, mitochondria-based drug, peptides of and on have therapeutics is regulate represent the have systems player keys the and Prior we even discover multiple body's Dr. mitochondria that. biological results, therapeutics. locks slide? on are peptides, taking research new large, obesity. functions. analogs. Ken we over NASH believe Dr. one-by-one the CSO, it as in of discovery, is are Next regulating the discovered X,XXX XXX the Barzilai over such genome keys CohBar scientists down they we lock and them potential cell therapeutics may on that and in in like wall multiple of untapped our class mitochondria based Amazingly, people open and exciting we body. group believe the and a the some in key a XXX to we Think new It opportunity, not of were Cundy leaders that we open. the powerhouses Based his in which to mitochondrial-generated developed our believe

evolution therapeutics range In and diseases cellular the diseases. work mitochondrial wide the mitochondrial symptoms. new with because are cause we X of that benefit we entirely We treating at targeting over the evolutionary years the approaches. targeting on peptides. associated approaches different so, just we to billion of will Mitochondria-based peptides problem of on has believe a We are from dysfunction. compounds, over may than surfing system and level, we have generate rather are mitochondrial And behind wave years. of need side therapeutic the body derived billion taking are biology therapies developing limitations evolved effects. the Many doing older mitochondrial advantage a that our new In X of peptides are and the the of

believe, with agents they side represent starting less reason, this we better For therapeutic for a developing effects. point

has the programs. technical our grown company's traditional peptide last two As to result, of to In compared five higher probability approach. may the success a have the a portfolio programs medicines from discovery year,

no exciting is are the really NASH program and a targeting a is It longer now focused time. just fibrosis and We company oncology. ARDS,

organs to new that is targeted new class of learn and We new therapeutics potential indications, new mechanisms this continue action. of things about

milestones leader a to comprehensive mitochondrial-based are assets. near-term we have to the demonstrating with property therapeutics, of development And expect into number We multiple a as our growth our company strengthening of intellectual clinical committed continued in position. a

We having a advantage. have first-mover from benefited greatly

first current to few had our program. we significantly plans, In candidate strengthened identification. for our slide? multiple Based finance CBXXXX like peptides our On our We I In ARDS us and identified our a after in results discuss investor on announced IPF agonist accelerating to the program did evaluating with call anti-fibrotic in to and preclinical plan we programs. into coverage said. to we pipeline, we a moving models. finances we continued last confirmatory of funds raise this activity announcing only of antifibrotic would Apelin our through to program, lead support We Phase in model can believe the accomplishments and XXXX. initiate obesity. Next a our additional months from order funds generated in XXXX, November, the forward four analysts as our NASH quarter our other of our Jeff are the CBXXXX program, take Now year. II program, moving both and advancement In and anti-inflammatory

year. next progress, We to that to move programs. we forward conducting the clinical potential be such are clinic have multiple subject have programs to three may And successful the planning in stage we

We continued continue significantly of about pharmaceutical presenting platform by in meeting featured And investors mitochondria-based in increase our being presence advance multiples with portfolio. Magazine. XXXX, year. and which to Executive publications such significantly our and Longevity we companies visibility then and the XX educating in at conferences and lastly, And increased Technology is Chief our media since BioSpace, we prior have as peptide

for the through Next milestones slide. near-term are These XXXX. XXXX

have We on top-line subject of the a funding, of visit, Based timing study CBXXXX activities patient to end Phase for the number the begin clinical trial. expect results Ib initiate factors, a half plan QX year CBXXXX-X study. last support first-in-human candidate In on a additional of and clinical expect from the second dependent at XXXX, last the visit. we new to including XXXX file in third IND select of to next we a and the the to the

programs, over for is generating then continue clinical few pipeline multiple studies the goal next lead overall years. which to to Our could the

with have we into the experienced stated our not is and each in of going are the Recently multiple clinic. multiple potential family They earlier as in of programs program these peptide transformation targeting development company to we the structures. have one different that the slide. Next compounds portfolio each represents Note are same indications. of a a a

provide to potential with shots portfolio on goal. true a multiple is this So

funding in Sail Interest bumpy remains ride companies. continues NASH received number the obesity development slide. high. some have companies of the NASH companies. some There later therapies went stage field public a NASH Next in of companies and of largest a last and pharmaceutical that for the biotech the of to be the year. of for funds from been These

shifted has communications. leaders from One of away FDA first in the NASH NASH to its focus response

and relatively clinical few several is readouts expected. as data of year, an ongoing companies For this other are described year as execution their quiet a are year trials later many stage

for believe need room the our therapeutic CBXXXX. is market, unique plenty the of mitochondria-based we for our complex disease therapies size multiple there potential to the given So novel of of this and mechanism manage action

we to Ib We will and do top-line through safety Finally in MRI-PDFF study CBXXXX. from data our obtain his study further and activity what the Phase measures Ken initiated begin expect data initial to humans of and our four-week clinical this from pharmacokinetics in explain exploring in order section. multiple biomarkers. the

slide. Next

our unmet treatment Drugs medical approved to cause a available currently of effects options. major clinical IPF remains significant slow their Turning few with use. can side for second can candidate the disease, but also IPF the that limit progression need

usually of difficulties recent world's detailed disease these shortened it on call. a IPF is experience foremost advantages companies orphan patients an in company medical consultant will first on indication Dr. our KOL that chronic, which and IPF experts Maher and fatal in the the the process. therapies. multiple progressive a focused expectancies One to disease Most provides the antifibrotic as the development with other area need working life likely Toby is

Beyond targeting mortality opportunity are diseases XX% IPF, range cause developed account all fibrotic the of liver, heart. in a different world. we organs, the and diseases for including potential lungs These in kidney, affecting a of broader

which slide. vaccinated. need. Even peptides unmet ARDS. often in COVID-XX sequences is from why remains syndrome asked, patients, if counting COVID-XX from being major continue develop medical without mitochondrial ARDS inhibitor of I'm found target to the distress a the worldwide derived we genome. are finally, also CXCRX patients ARDS million our three Next respiratory And everyone acute suffering were peptides, There

Next slide.

Now the call turn Ken? I to will over

Ken Cundy

give in our programs. I'll development update a Steve. research key now recent brief Thanks, on progress and

Next slide please.

testing of have recently of is we Ia/Ib So we enrollment for and the the the clinical stage potential also Phase of NASH that let's Ib study program. treatment clinical stage a the start Ia is with in study. CBXXXX obesity. The as and currently Phase announced completed completed Phase the

Ib CBXXXX fat obesity fat a XX study have XX on a provide effects Phase study, Ib this and screening. liver given CBXXXX of weight in XX% reminder, one stage required and of on Phase target is are measured body The by of with a the designed so NASH in biomarkers NAFLD study This by dose deal even of is MRI-PDFF top enrollment second and the to study stage further end be of metabolic potential currently completed pivotal with various that XXXX have the had to are liver in the subjects unpredictable due subjects relevant as state. recently, COVID-XX Now study during one at We a on safety Changes once-daily expect double-blind subject placebo status active all placebo-controlled short Texas at with fat, the of this quarter line to to final assess visit. obese we is injection. on sites. were study of at has liver a impacted and trends on XX level tests last and when their We results order testing to subject not which were routine ice to baseline a will disease. for data. II enrolment, more in And related minimum Phase impacts despite to the able that the expect enrollment earlier of positive the the again to even looking across of COVID-XX any the in have included the complete we've we study regions update to our many follow-up issues, factors of dropouts pause, slower to storms the lab

slide please. Next

the the has been process we a clinical this last enrollment. trial for as on rolling study So call, discussed

shown are each up for and as new simplified diagram, process a there's followed observation by This the has last this for their last study dosed subject When final subject in was period safety. enrolled subject the there follow-up each shown until diamond. issues. to dose, safety receives As still follow-up no continues completed ensure

entered body the Only database. meaning have throughout errors, all who collected, all is safety be subjects the for When fat, the been cleaned, we the systematically data yet data then and errors placebo. analysis of collected this liver all at stage, then weight will are are required data all the who are checked will data received still locked. and pharmacokinetics, Now entire and into the final process visit are CBXXXX and resolved biomarker for levels have this and database received after blinded follow-up do not then the And finally data a completed, and unblinded know begin. data

Next slide please.

The safety study? the outcomes. expect Ib So of the out endpoints possible Phase this multiple the we what study there primary can tolerability. are Well, of and are

effects and either from NGM, they have A DURECT Hepion In companies at they Merck, including looked number Metacrine, others, studies released subjects. some liver changes. or In sometimes fat of data shown? cases, will changes NAFLD four-week be biomarkers with body they weight other several what there studies pharmacokinetics. subjects outcomes The that analyzing endpoint in similar NAFLD looked the four-week in at at or of we NASH biomarkers both. same trends. NASH and that subjects. subgroup a trends significant looked about statistically for study have positive While of studies published were precedent will these four smaller NASH detected and a liver of after historical have only one types weeks There the to secondary was range be dosing outcomes wide changes in compounds? include exploratory The study period. the And activity in endpoints for least What been at of a after these and using either trends treatment in from in studies have four-week other fat, the

CohBar's and best other be Xb. clinical completely give drug. which differences the of mechanisms potency already important prior are of their So also some different between There drugs have in action of meaning of a and there range knowledge of already about with been some this and way sense was these validated some result indications, the the testing outcomes studies to Phase may

Our confined studies from no and of underlying And the agents to attempt to studies. control prior placebo for study mechanism to group designs, were those of is CBXXXX conceal investigators identity unique was the some published subjects were action while was study, our has no there the duration a of studies, a open-label the meaning the demonstrate compared there placebo assessed or the those controlled treatment subjects in the earlier double-blind the unlike of also their treatment. effect.

the to is need of this CBXXXX, top As will first-in-human line data. obviously study we for wait the

slide, please. Next

Now let's Phase NASH with obesity NASH, including corporate and talk Xa/Xb plan study what's the next study and for a about the CBXXXX. for with to prepare We seeking clinical readouts next partner. complete in ongoing

initiate Now and a potential Phase X positive fundraising, and XXXX general based then clinical partnerships study XXXX. preparations funding in additional initiate results for X on then from plan we Phase and to in

Phase design evolving the we primary take endpoints. must will four plans depend we to of of Phase secondary forward, regimen or for we another Phase have in Our need and appropriate clinical small that involving is a biopsy the In X reduction on and be a we liver regulatory fat there will of be larger treatment, dose in biomarkers. Based looking factors select on need landscape same longer as a XX is the planning weeks number duration by the see most the trends understand not NASH for Xb outcomes, study and MRI-PDFF that Xb outcome, regimens trends study how duration outcomes optimum clinical This so normally the of XX such in to study, another driven the for studies around what the data to and weeks. study from or for considered. are terms

GLP-X We for fibrosis select other mechanism CBXXXX a of the diabetes population product. most advantageous It take the to consider study and differentiate will to on of a diabetic use may agonist NASH in appropriate our with the need of potential study synergy our population. population comorbidities and carefully be full potential to patient drug, contribution to advantage stage right the help and

in towards need conclude development, and And will the to necessary And our we to continue final we X refine Phase including commercial alternative we a the independent remaining preparations, any indications. at also form. cetera. potential obesity Now possibly to toxicology, all look NASH et outcome, formulation we progress in other as of for will manufacturing then continue CBXXXX

Now stages the disease. in utility complex suggests or described like synergistic And accumulation a and mechanisms address fat agonists a inflammation There the involving fibrosis, liver ultimately multiple in as that CBXXXX that can different be to continue treatment disease setting. be other failure of combination combination is to NASH will we from and in used need to previously is GLP-X to these progression some for cirrhosis mechanism the of the liver a options eventually that with of treatment potential cancer.

please. slide Next

the let's mitochondria peptides and family pulmonary related on Now of preclinical antifibrotic vitro or of or in properties molecules IPF. novel strong showed a coated CBXXXX analogs, peptide to models move that idiopathic in multiple with antifibrotic in anti-inflammatory our to and vivo program, fibrosis these are

therapeutic analogs this models improved of studies the positive in after reducing induction all of process effects cells. levels in human multiple inflammation. cytokine discoveries cells IPF. cells, the pathological had therapeutic efficacy of and on these demonstrated secretion with model, fibrosis, key fibrotic collagen, of We week on one fibrosis initial demonstrating further vivo, In long on in involved bleomycin the CBXXXX study therapeutic prophylactic outcomes, two We've standard produced drugs approved then effects one appear same that showed CBXXXX anti-inflammatory current showed treatment lung to nintedanib effects of with those alone. the nintedanib dosing in by we and care healthy than based a the and the using of analog analogs, and the proteins greater lung IPF And combination model, model. we of with of cell antifibrotic, cultured to the production built animals of therapeutic from reducing fibrosis the Now and clear by beginning transformation animal the fibrotic inhibiting of peptides in conducted work

Additional are ongoing. combination studies

proof-of-concept. fibrosis. we monotherapy the of clinical idiopathic a Most CBXXXX-X as recently for candidate importantly, clinical likely will However, a initial announced pulmonary for treatment new the use nomination we potential

fibrotic IND-enabling plan have same anti-fibrotic in We CBXXXX time, to clinical analog start At them and suggests, kidney file of anti-inflammatory using exploring models activities, an that XXXX. treat the setting systemic potential effects We're initiated other potentially now to there sclerosis, the and IND is such broad in we a fibrosis. diseases. potential for studies NASH, the preclinical in and and as

this Next slide, see the data some therapeutic of released at Thoracic we slide model were American please. Meeting. that is the Society mouse Virtual On of for efficacy last as Annual that final IPF. This of candidate CBXXXX-X the the at monotherapy, looking peptide using year

fibrosis, So bars, green week bleomycin in induction the vehicle shown red in placebo our with were bars, orange the CBXXXX-X of nintedanib one after the animals bars. treated in

nausea progression here also said lung And and in Now you secreted of in It's But two of of lung of the nintedanib, and is IPF. the diarrhea. see effects, levels significant the anti-fibrotic the including to into targets and fibrosis, in and has consistent across inhibitor I terms fluid. of slowing nintedanib lung anti-inflammatory lung weight, effects inflammation collagen lymphocytes both different IPF as reductions drugs. tissue one approved in leading several board, kinase has CBXXXX including the blocks vomiting a tyrosine that off-target

did treat animal lung an control, receive of given and some lung tissue example please. lung the with bleomycin you animal the healthy an slide here, that to is an left, inflammatory bleomycin. tissue significant weeks And from photomicrographs we cells. these tissue of of not and vehicle mice. see Next the for see from Top of two it infiltration shows fibrosis induce it right, Top then fibrosis

of followed animal an bleomycin inflammation. bleomycin the of nintedanib more of On the the the is by see we CBXXXX-X lung and care. the the reduction by given right, followed inflammation. and even given in fibrosis on the fibrosis less bottom significant There standard an left, lung is animal But bottom

slide Next please.

of treating at into case, lavage induction study this we're week cytokines. the for of no we XX before In lung these levels of the therapeutic levels model pro-inflammatory IPF. waiting Here of Treatment cytokines. contrast, nintedanib mouse with on with or either looking CBXXXX-X. fibrosis, effect the treatment In of secreted pro-inflammatory of see nintedanib cytokines, with had another fluid, in reduced days all CBXXXX again, these the after a vehicle levels

please. the XX inflammatory lungs. into the study, of macrophages the treatment slide a the Next looking treatment. we're infiltration CBXXXX-X lymphocytes cells here with levels the in the days lung And for end neutrophils produced reduction cell and levels in treatment with the of same at reduced infiltration, And by nintedanib from but greater of of

slide please. Next

But in considered which bit are include We into process candidate So evaluate Obviously, to this new in now at about physical That's There we We structures specific about which incorporates chemical properties way we suitability that selecting approach. let's the an changing talk in indication. how models. in a iterative drug-like like go vivo the design be improve analogs the little the and efficacy their route metabolic improvements administration. process. can't of selection that optimization factors look properties, we their pharmacokinetics, analogs in generate of of intended design. their various clinical target the to look go vitro models animal stability, many or in in into We analogs final properties. we and for need part things our candidate. and at proprietary

activities complete peptides useful as to potential are CBXXXX-X CBXXXX-X is FDA that preliminary backups. a factors We that are and synthesize look support several beyond at easy need the clinical And other are there data. also as submission still step potentially use. to there are they or candidate. But commercial process, need Out eventual The to scale up for we to IND for consider will the of this the and study. that clinical other involved. We safety first-in-human lead necessary next to how identified IND-enabling have

we've cannot NIAID acute Next update evaluate that under slide our treatment are model as development our of something agonist of signed the the in and the distress efficacy SARS-CoV-X National briefly agreement, model with data please. of potential has lungs announced under the conduct on be syndrome, provide COVID-XX model analog an lung related Apelin NIAID. may changes agreement and of be is NIH, a ARDS. ARDS. for we non-clinical could lastly, on been ARDS peptides the hamster for in Infectious and of And the acute available. Institute is that this a reported the analog give of study model and That expense of respiratory timing Well, now as so hands family COVID-XX the the patients CBXXXX at I'll COVID-XX the Diseases, The with program. infection. of to in that reproduce their will their Allergy previously guidance when some We evaluation such CBXXXX seen This

look to ARDS COVID-XX we'll meantime, effects in that we available model continue the general opportunity However, of ARDS. do the protective CBXXXX in to to analogs assess in for move of program to this the forward forward related And resources. subject

slide Next please.

hours levels the of bronchoalveolar reduced is analogs that fluid. cytokines four of cytokines the a at some then and received lipopolysaccharide these LPS lavage see same from the collected Now, peptide the characteristic in in we that cytokine The And slide, LPS-induced these was the acute model at efficacy using single COVID-XX key We lungs a follow-on CBXXXX injury. part induction. of the are ARDS. that after looking dose recent severe analogs of cytokines This or from data one LPS are mouse found a pro-inflammatory lavage inflammatory in that administration the hour study before animals bronchoalveolar of of this and the of the fluid ARDS. we're present are storm analogs involves CBXXXX here lung levels

So, of resources. will after we're and program move availability selection candidate continuing as forward mentioned depend further to I this on development

call So, with that, Steve. I'll turn the to back

Steve Engle

Ken. Excellent

Next would see year about CohBar. and closing, slide. as to we In I speak like for our why priorities a this transformational

into studies preclinical in our our And Our two CBXXXX-X results of on across a study. pleased trials in pipeline IND-enabling Phase board of XXXX advancements to to topline execute year. continued priorities the generate studies the in multiple the the From to with are indications programs. the conduct believe to first-in-human And year plan, and we why multiple I rest conducting number see am three, preclinical potentially forward to number from this can enable represents to Ia/Ib you bring from pipeline. continue clinical next XXXX. progress look our change studies

Given We the the last potential of have we to a new our mitochondria-based pandemic, We on patients. with opportunity delivering class special remain I'm committed medicines of forward year's execution. pace bring with pleased of also impact for promise science therapeutics. to of the that know a

participate who by like to clinical would in studies, and I many people including my healthy Finally, patients physicians. the our end the remarks volunteers, thanking

thank the reality. at also great every team to We working to would this make vision a like CohBar for hard day

believing shareholders loyal Lastly, like our vision. thank our to in for I'd

slide. Next

the questions answers. turn we'll the line Now for and to line over open operator to the

Operator

Thank you.

now session. will you. conducting [Operator We question-and-answer be a Instructions] Thank

Our first proceed Morabito with Capital question question. from your comes with Please Michael Chardan Markets.

Michael Morabito

Thanks for questions. Steve. taking the Hi,

liver for over fat. early I specifically bit XXXX, just NASH try numbers much regarding all on can report your a and the be of as to lot liver the the So fat come wanted impacted. especially as a far compounds seen is place out We've how fat And trials. of liver data, from to expectations little touch

that I to not they impact Texas. did anything, action, for you visits for finally, to nominate for? enrollment, affected roughly of a third on know I'm you'd the be and reduction but new the the mentioned the that you to that had they And been enrolled. end that also candidate already or they mechanism looking by patient think like the ARDS based this you've also patients find affect on -- but fat roughly year. haven't liver should a of likely wanted out impacts Do what you new that in that me that is if or involve kind or something I COVID be delays we more from would talked XXXX in So something about ice heard get about before, maybe would number trial maybe before? we to be is that are something looking CXCRX of the And due storms expect

Steve Engle

Ken?

Ken Cundy

Yeah.

Let question. for a Thanks at me Michael. time take those one the

first aware week the liver have What said XXXX studies as fat been expectations. So about several you're and conducted. one the and four I

varied. NASH some liver presume in or and have NAFLD quite fact the NASH in are been you Some as said changes are

very trend liver see, be change setting out over that prior number much fat hope observations liver fat. difficult it's based But predict a fat a week looking treatment. but to for significantly in see so on impact think period. of again, would necessarily not trend for would I to we It able possible duration is as a four a expect in us to to powered that in to we that we're liver significant of the

as we four question the mine. was As will your what's but studies, far COVID-XX. ice directly from other On as clear subjects guess we having had COVID-XX what your go and humans far from the generate can impacted clinical dosing. published their from as which a data their mentioned, at studies visits testing. became for the hasn't on safety to that think. is that's in to Yeah, to study we the a ability time study week unrelated for animal that as We've predict about pretty storms those I good as can't came the the infected dropouts COVID-XX been other We them and of completed of related be that's end number, second the as number and their have fact as impacts back positive after did later

third to third we've your complete process positively couple said, the through of have subjects our about to subjects the that's because now opposed this and enrolment, as visit. was study then And their tested. awaiting to as out a are get completed minor that our they component achieved target question last up drop less candidate. But follow So of and we

So next that's yes, from case models available there on CBXXXX-X, the program, on that something ARDS stimulating a fact agonist see expect likelihood are activity course the process resources. candidate that Apelin is demonstrated started move clear would of be of the We've have ARDS the based the from and to that the moving come The pathway, step the also will these selection. a with candidate in of now acute I we is there the think for course in we and same but multiple that lung we've dependent injury select towards through that just models. we is progress

three So let brought hit I out the me know, you things have on there Michael?

Michael Morabito

Yes, you have. much thought. Thank the very for you

Ken Cundy

Michael. Thanks

Operator

you. Thank

question with Capital proceed comes Our your with Please from Partners. next Piros Elemer ROTH question.

Elemer Piros

housekeeping so the expense higher that with Jeff, you R&D events it Jeff. I thank pre-empt quarter confluence much. you was made a onetime quarters. mentioned previous fourth of I Yes, that could think than if Maybe question a

be expect Looking forward at than if estimated you higher to increase based trends, that the right previous range? $X million range, look would would were you do expenses, that XXXX to the $X.X on to or million

Jeff Biunno

for Hi than get as Elemer, be that base as that through. slightly probably will we the call. a It thanks higher and

we trial, the sort the As this through going to cost get the to and start clinical of through programs incurring now pushed that we're year.

probably programs. the bit be in invest that in the more higher well we as other So, around we'll as that to than a R&D,

Elemer Piros

$X of and million north So some...

Jeff Biunno

said you I'm what hear sorry? didn't I

Elemer Piros

to? North of $X you're million what referring that's

Jeff Biunno

Yes. Right.

Elemer Piros

Okay.

back And could Okay. XXXX Thank you you. Ken study. to just the come if

and on? concentrate biomarker top You Which biomarkers focus that and or those a you release. number collecting the efficacy you're information would on line of listed in of safety

Ken Cundy

would ones top data -- information line our listed. all the on definitely have have time We by the we

you entire follow-on do. a you magnitude those certainly that data as know there's sense you to as So lot many get we outcomes an of will list. have need But analysis that as initial of across of far when that -- trends

we our to the those top to impact towards quarter specifically be each data when on able expect we out tell what line So first of the second was end biomarkers. would of put

Elemer Piros

the patients have number in rate there is of the biomarkers analysis? that sense good or have at good points you far And completion collection XX of these as fairly for that data Right. you as multiple a that you subjects XX or the time need points

Ken Cundy

Yes. because -- are the confined Elemer duration is treatment. we And of part of for these that are subjects

much biomarker assured definition, we a by are weekly of basis. taken are access to So readouts. on And many these pretty having of

out readout. So this quite we'll of lot have of data a

Elemer Piros

that could testing? you doses are if And in just arm active you how us lastly remind many the

Ken Cundy

placebo versus head-to-head of level active dose in Ib. the one There's

and that dose was Yes. a duration used. that's the of it's dose subcutaneous it injection. out the Ia So same being clarify dosing is once-a-day of selected by just the for to the X-week Stage But study

Elemer Piros

your Got help. so much it. you Thank for

Ken Cundy

Elemer. thanks Sure,

Operator

Thank you.

with Please next comes Securities. question. from your Our Steve question Brozak proceed WBB with

Steve Brozak

taking good gentlemen. And Hey, afternoon for thanks questions.

programs, asking on single importance people and COVID be specifically of just But possible I a COVID? a lot you around critical because programs its Thank And where now Just guess, as give I'll about the at the interested your And would focus one, can of for what guess specifically I'm as detail is you. the much the haulers. as looking simply issue. area I in And that queue. is, hop back CohBar long them? in turned are

Jeff Biunno

Ken?

Ken Cundy

COVID question. as when consequences have healthy Yeah. a as are people to the happens It's you're long-term of Thanks, hospitalized that Yeah, an not Thanks life. just what infection. Yeah, you the that absolutely right. the you're for situation effects or and is There infection. the you take Thanks, returning you're I'll recover think Steve. and many evolving downstream one. far Steve. squally

issues. in well. COVID as of things evidence in thrombotic Some of ways fibrosis, like, initial locally of result injury There's of terms as a in different these the caused are by persistent manifesting the lung lungs

infection mutation strains very everyone there because there And and be we When So, have of and for need many vaccinate re-infection as long-haul sure strains, to occurs are ways continuing with issues, obviously possibility to COVID treat we even of emergence where you familiar as new new vaccinated then but pockets as of emerging. of just will will these after people subjects because are not unable can. occur. I'm you're continuous the the

what the but of has are in which longer-term in So setting And just COVID is, indications. somewhat we related treatment COVID directions many with of our other Apelin to not see the for current with downstream go damage COVID the acute actually overlaps infection to vision the caused. that the related agonists the possibilities issues

may COVID, we our program used very apparent. peptide. could as an if you to haulers be antifibrotic fibrosis it setting is not current asset COVID, but well in Apelin So targeted the more agonist be think about have long becomes now the that of That an for fibrosis

Steve Brozak

people grasp that lot that things you those was Great. the a just one again. for Thank of detailing, don't totality because of you of Thank it obviously it.

Ken Cundy

Yeah. lot Thanks Steve… a

Jeff Biunno

Thanks.

Ken Cundy

Thanks the question. for

Operator

Brookline. Our [Indiscernible] comes question proceed with Please with question. [Operator from your next Instructions]

Unidentified Analyst

wondering Hi. you business studies the Thank behalf I'm move plan CBXXXX, you it. to your related And for could on if with question I light asked, COVID-related with quick you. ARDS was regarding to program. update. I some just the a from Steve how Brookline. Thanks what had of Kumar on throw

big you partnership with or In the in space? ARDS do have to expect possibly studies diabetes the maybe Pharma, terms clinical of

Ken Cundy

good a question. that's Yeah,

obviously As progress that as entry. towards the Then longer-term the at near-term for affected the same setting, population or would pathways. we so healthy would ARDS, that readouts probably be far clinical a we're the design by Apelin subject initial demonstrating non-COVID-related and looking signaling

SARS-CoV-X readout in ARDS? ARDS. of are more of I having proof-of-concept So on cytokines initially into those effects that would study we setting driven take the what we So, in is kind circulating the how forward mechanistic if think there by a course U.S. results ARDS added we we get from that change, that the setting those may the be program And in convincing are based government the interest see may if on now of momentum outcomes. in

Unidentified Analyst

Yeah. Okay. Thank you.

Ken Cundy

to Steve but... wants that, to add

Unidentified Analyst

Okay.

Steve Engle

Ken. great, was that no, No,

the and only other this there's I'd two there's disease of the think is acute chronic. There's that, sides the I right? thing add situation

partnering another in and forth. thinking about piece so that's So

Unidentified Analyst

Correct. Thank so much. you

Steve Engle

you. Thank

Jeff Biunno

you. Thank

Operator

you. Thank

question from next Capital. Our comes Nathan your Please with Aegis question. with Weinstein proceed

Nathan Weinstein

for update and my Thanks afternoon. question. good Hey, taking the for

peptide So peptide know you've and I perhaps potential a derived analogs. itself, talking see wouldn't of you I suppose bit the about we XXX the could platform mind mitochondria the over the discovered just X,XXX you start little

of seen range could in peptides even you've the indications those you variance perhaps stage? the could beyond maybe speak what's about perhaps clinical they and address the So

Steve Engle

Ken?

Ken Cundy

Yeah.

take that Let me one.

surface of interactions you just derived to MDP points there original there founders is generating and broad just scratching We mitochondria list that range right? the peptides work of are, signaling think so now MOTS-c, of. are they're a the So Obviously humanin that a SHLPs our uncovered and like that and are is mitochondrial here we from but what the ATP. when that first it possible things definitely question it's they not great just it organ these the from ALS know not

We are Again terms of and we find uncovered and target said using improved and and of those phenotypic We're screening the what have we're doing. outwards in what things from they as their are capable surface screening moving go targets. like analogs hundred try sequences doing, scratching guess they over there. to and

in as case potency. the Sometimes CXCRX very clear that's which of the antagonist, nanomolar have

are other effects the are the definition by at. looking be more some And a in of settings purpose. still useful. other effects the the to in So target. case we're clear cases and highly than evolved That But and very the that would protective strong

the apoptosis of immune like control control answer settings. indications. that larger we're these system. is no many more as of there's aware a across test cell we'll with we metabolic focused going We Initially but even where opportunities the here proliferation. different they're we paradigm control related, to are weren't we things mitochondria than They range that. on So in be find metabolically the because involved things. They think mitochondria They indications

uncovered yet is which possibility we've indications, there broad that appreciate. regulatory peptides that a used different So some of be these we many could don't in

Nathan Weinstein

It's, follow-up. thematic that appreciate just go sort really I suppose around answer. one I Yes a It's you. the -- Thank longevity. very I And ahead. interesting. question have of,

Steve Engle

that. exactly it No, was

headed in direction. You're that

other increase longevity Barzilai field, by the work other as in as an as indications and oncology around of the areas. Cohen metabolic also well besides well there's as collaborators and So

can through that's in so there's you it. the what might published be indicators possible. been range out And of And of see there, can a you work go broad

time diseases, and -- some so avoiding is And big in a you of think have that longevity. with period their help that people total terms health span their do these as I probably you on impact of will

that way on think drugs the we Obviously and target most the people there's longer. diseases in certainly outcome are the whether as here that of think it's so aren't United I at be well get with approved possible otherwise States well. aren't living or a some but with the diseases, a specific longer people reasons these point key situation will recognize And living cardiovascular some that

that that think there opportunity I so And is well. as

Nathan Weinstein

Yeah, thank you.

much think I pretty You anticipated more my than transparent always you've very am nicely. coming, so that and saw I'm I question

I So the appreciate color.

Steve Engle

you. up down. suddenly be would And and be just if I body, of Well, be another was knew in pretty XX were people new the someone there day, scientifically thank say the it other And those, mind-boggling. discovered want would to if you I there with five you jumping hormones

executing five any we know matter all got discovery executing on. And it. part it that his is think there And what Yes, so But the absolutely. It's are team do yet. far, process they programs a on of more? and really And do moving I are don't Ken of forward. we've means by

different As preclinical we've these it's the clinic. program, programs as and shown the and a beginning of as results, figure approach the what progress, towards this And we to in as matter time year, money we've compounds last to clinical staging do. out move well made big both in our those

the machine think right working direction. the I So, in is

excited we're So, about that. very

Operator

Thank you.

Greg [ph] Wan Investor. your from Please with comes Cowski with proceed question next Private question. Our

Unidentified Analyst

the you second how on million abilities were the from I Russell is, XXXX accomplishments Hello them My my XXXX. your one here in in question of XXXX, being Yes. to added half? finance for removed your financing, call. Thank your forward operations you going and Russell see $XX.X affect is the gentlemen. to it your taking raising

Steve Engle

question. to call. we're the this really And appreciate on able anything yes, not that be going say about I to

directly it. more and forth. so mean can't involves about sorry, speak stock price So directly. I we Because it

we but all -- of the So are well possibilities. aware

Unidentified Analyst

my Okay. question. was Well, that you. Thank

Steve Engle

Thank you.

Operator

this the Engle like any to comments. no I questions closing would Steve time. floor turn you. for at are back over There Thank further to

Steve Engle

that, Phase I promises company. record are and moving than usual have probably in been forward And delivered results and on Ib continuing in the soon. many we been investors, forward fact, more for resources to particular we've months. to the a over biotech that looking of Well, have feel the We've kinds XX funds. hope as doing within it consistently we a you last And

Thank very So stay tuned. you much.

Operator

conference. today's concludes This

and wonderful You your you a for have Thank time. participation may this your at evening. disconnect lines

CohBar (CWBR) 31 Mar 212020 Q4 Earnings call transcript